EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization

Aditya Mahadevan iD, Aidan Vosooghi, Jagmeet S Arora, Ruthvik Sunil Kumar, Gagandeep Singh, Katy K Tsai, Zoe Quandt iD

The Journal of Clinical Endocrinology & Metabolism · 19.05.2026 · 111 (6) · 1604-1612

DOI: 10.1210/clinem/dgaf703 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 02.01.2026. Verfasst von Aditya Mahadevan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Neoplasms, Metformin, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been reported to decrease cancer incidence, but less is known about their potential in patients with active cancer. Preclinical studies have demonstrated that GLP-1RAs inhibit progression of solid tumor malignancies via downregulation of cellular proliferation pathways and improved glycemic control. Despite these promising findings, studies characterizing the effects of GLP-1RAs in patients with active cancer are limited.

Objective

To evaluate the effects of GLP-1RAs on mortality and hospitalization in patients with type 2 diabetes and active cancer compared to those receiving metformin.

Methods

Using TriNetX, a global database comprising more than 120 million patients, we identified an overall cohort of 3747 patients with type 2 diabetes who received GLP-1RAs within 3 months of starting systemic therapy and identified 52 061 patients receiving metformin in the same timeframe as a control cohort. Additional subanalyses stratified patients by glycated hemoglobin A1c (HbA1c) range, obesity, and by participants “newly started” on their first instance of GLP-1 RA within 3 months of starting cancer treatment.

Results

Patients receiving GLP-1RAs had significantly reduced mortality both in the overall monotherapy setting (hazard ratio [HR]: 0.875; 95% CI, 0.778-0.985; P = .0268) and the new-start setting (HR: 0.786; 95% CI, 0.662-0.934; P = .0062) cohorts. Secondary analyses found lower rates of all-cause hospitalization, sepsis, major adverse cardiovascular events, pulmonary embolism, and pneumonia in patients on GLP-1RAs. Subanalyses stratified by body mass index and HbA1c did not meet statistical significance.

Conclusion

Patients with diabetes and cancer who received GLP-1RAs experienced superior survival outcomes and reduced rates of hospitalization compared to patients receiving metformin. Additionally, patients already on metformin and newly started on GLP-1RAs demonstrated superior survival outcomes compared to patients newly started on insulin. Further prospective, well-controlled studies are needed to evaluate the benefits of GLP-1RAs in patients with diabetes and cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2NeoplasmsMetforminGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsProportional Hazards ModelsHospitalizationTreatment OutcomeKaplan-Meier EstimateHumansMaleFemaleMiddle AgedAgedRetrospective Studies

Stichwörter der Autor:innen

GLP-1RAcancerdulaglutideexenatideliraglutidesemaglutidesurvivaltirzepatide

Substanzen

MetforminGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Department of Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
  • School of Medicine, University of California, Irvine, CA 92617, USA.
  • Department of Medicine, University of Kentucky, Lexington, KY 40506, USA.
  • Department of Computer Science, University of California, Davis, CA 95616, USA.
  • Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.

ORCID-Profile: Aditya Mahadevan, Zoe Quandt

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Mahadevan, A., Vosooghi, A., Arora, J. S., Kumar, R. S., Singh, G., Tsai, K. K., & Quandt, Z. (2026). GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization. The Journal of Clinical Endocrinology & Metabolism, 111(6), 1604-1612. https://doi.org/10.1210/clinem/dgaf703

Vancouver

Mahadevan A, Vosooghi A, Arora JS, Kumar RS, Singh G, Tsai KK, et al. GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization. The Journal of Clinical Endocrinology & Metabolism. 2026;111(6):1604-1612. doi:10.1210/clinem/dgaf703

BibTeX
@article{Mahadevan2026,
  author = {Mahadevan, Aditya and Vosooghi, Aidan and Arora, Jagmeet S and Kumar, Ruthvik Sunil and Singh, Gagandeep and Tsai, Katy K and Quandt, Zoe},
  title = {GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {6},
  pages = {1604--1612},
  doi = {10.1210/clinem/dgaf703}
}
Kostenlos starten →